143 related articles for article (PubMed ID: 37961884)
1. Rigour and science in drug regulatory approval.
Abbasi K
J R Soc Med; 2023 Oct; 116(10):323. PubMed ID: 37961884
[No Abstract] [Full Text] [Related]
2. The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.
Abbasi K; Herxheimer A
BMJ; 1998 Oct; 317(7163):898. PubMed ID: 9756800
[No Abstract] [Full Text] [Related]
3. Efficient drug approval and monitoring must rely on sound regulatory science.
Meagher EA; Fitzgerald GA
Nat Med; 2011 Dec; 17(12):1535. PubMed ID: 22146443
[No Abstract] [Full Text] [Related]
4. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.
Sanyal AJ; Miller V
Gastroenterology; 2016 Jun; 150(8):1723-7. PubMed ID: 26924092
[No Abstract] [Full Text] [Related]
5. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan.
Hirakawa A; Sato H; Igeta M; Fujikawa K; Daimon T; Teramukai S
Pharm Stat; 2022 May; 21(3):691-695. PubMed ID: 34994060
[TBL] [Abstract][Full Text] [Related]
6. Trends and Characteristics of New Drug Approvals in China, 2011-2021.
Su L; Liu S; Li G; Xie C; Yang H; Liu Y; Yin C; Chen X
Ther Innov Regul Sci; 2023 Mar; 57(2):343-351. PubMed ID: 36322325
[TBL] [Abstract][Full Text] [Related]
7. Advancing a Vision for Regulatory Science Training.
Adamo JE; Wilhelm EE; Steele SJ
Clin Transl Sci; 2015 Oct; 8(5):615-8. PubMed ID: 26083660
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
Sinha V; Zhao P; Huang SM; Zineh I
Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
[TBL] [Abstract][Full Text] [Related]
9. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
10. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Br J Clin Pharmacol; 2021 Aug; 87(8):3279-3291. PubMed ID: 33511674
[TBL] [Abstract][Full Text] [Related]
11. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
12. Rapid drug access and scientific rigour: a delicate balance.
The Lancet Neurology
Lancet Neurol; 2021 Jan; 20(1):1. PubMed ID: 33340471
[No Abstract] [Full Text] [Related]
13. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.
Zineh I; Woodcock J
Clin Pharmacol Ther; 2013 Jun; 93(6):515-25. PubMed ID: 23571772
[TBL] [Abstract][Full Text] [Related]
14. [Science of new drug development and regulatory review].
Ono S
Nihon Yakurigaku Zasshi; 2011 Dec; 138(6):252-5. PubMed ID: 22156263
[No Abstract] [Full Text] [Related]
15. Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug Development.
Tanese K; Yamori T
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):6-10. PubMed ID: 31608600
[No Abstract] [Full Text] [Related]
16. Advances in regulatory science at the Food and Drug Administration.
Psaty BM; Goodman SN; Breckenridge A
JAMA; 2013 May; 309(20):2103-4. PubMed ID: 23695478
[No Abstract] [Full Text] [Related]
17. Industry One-Voice-of-Quality Solutions Management Review of Post-Approval Changes Guide.
Vinther A; Mohammed F; Ramnarine E
PDA J Pharm Sci Technol; 2021; 75(5):454-457. PubMed ID: 33723006
[TBL] [Abstract][Full Text] [Related]
18. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
[TBL] [Abstract][Full Text] [Related]
19. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
Psaty BM; Meslin EM; Breckenridge A
JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
[No Abstract] [Full Text] [Related]
20. An open science pathway for drug marketing authorization-Registered drug approval.
Naudet F; Siebert M; Boussageon R; Cristea IA; Turner EH
PLoS Med; 2021 Aug; 18(8):e1003726. PubMed ID: 34370737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
